IL1R1 Inhibitors
2 drugsAbout IL1R1
Interleukin-1 receptor type 1 (IL1R1), also known as IL-1, is a cell surface receptor that initiates intracellular signaling upon binding the cytokine interleukin-1 (IL-1). This signaling cascade plays a critical role in inflammation.
Human genetic studies provide strong support for IL1R1 as a therapeutic target, with variants linked to antisynthetase syndrome (score 0.74), allergic rhinitis (0.64) and eczematoid dermatitis (0.64). Colocalization analysis reveals 20 strong eQTL/pQTL signals (max H4: 1.00).
IL1R1 is targeted by two FDA-approved drugs, ILARIS and KINERET, spanning immunology and other therapeutic areas. These drugs include one antibody and one biologic (other) modality.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Diffuse Large B-Cell Lymphoma with only 2 trials.
Human Genetic Evidence Strong
Genetic evidence provides strong support for IL1R1's role in multiple diseases.
Strong genetic support (max score 0.74) may increase clinical trial success probability.
Evidence Across Diseases
10 totalGWAS and other genetic studies link IL1B to 10 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for IL1B colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Novartis and BIOVITRUM AB are the companies with approved IL1R1-targeting drugs.
The presence of only two companies suggests a market with potential for new entrants.
Drug Modality Landscape
Modalities
Routes of Administration
IL1R1 requires biologic approaches (biologic (other)), likely due to its structure or location.
Consider novel modalities to differentiate from existing IL1R1-targeting drugs.
📈 Modality Evolution
other biologics pioneered IL1R1 targeting (2001), with antibodies entering more recently (2009).
Clinical Trials 217 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 51 | 29 | 13 | 9 | 69% |
| Phase 2 | 107 | 63 | 22 | 21 | 74% |
| Phase 3 | 49 | 29 | 11 | 9 | 73% |
| Phase 4 | 10 | 3 | 3 | 4 | 50% |
Top Sponsors
By Modality
Drug Approval Timeline (2001 - 2009)
The first IL1R1-targeting drug was approved in 2001, and the most recent in 2009.
The relatively long gap since the last approval suggests a potential for renewed innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 135 clinical trials targeting IL1R1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities